EP0007450A1
(de)
*
|
1978-07-07 |
1980-02-06 |
Ciba-Geigy Ag |
Azatetracyclische Carbonitrile, ihre Herstellung, pharmazeutische Präparate, die diese enthalten und deren Verwendung
|
ATE9159T1
(de)
*
|
1979-12-10 |
1984-09-15 |
Ciba-Geigy Ag |
Azatetracyclische carbonitrile.
|
FR2504140A1
(fr)
*
|
1981-04-16 |
1982-10-22 |
Centre Nat Rech Scient |
Nouveaux derives tetracycliques de la dibenzazepine, leur procede de preparation et les compositions pharmaceutiques en renfermant
|
DE3372369D1
(de)
*
|
1982-05-18 |
1987-08-13 |
Hoffmann La Roche |
Pyrrole (3,4-d)(2)benzazepine derivatives
|
JPS62101941U
(es)
*
|
1985-12-16 |
1987-06-29 |
|
|
IE62754B1
(en)
*
|
1988-08-26 |
1995-02-22 |
Akzo Nv |
Tetracyclic antidepressants
|
EP0569096A1
(en)
*
|
1992-05-08 |
1993-11-10 |
Akzo Nobel N.V. |
Depot preparation
|
ES2193158T3
(es)
*
|
1993-04-06 |
2003-11-01 |
Abbott Lab |
Compuestos tetraciclicos agonistas de la dopamina.
|
DE122010000050I2
(de)
*
|
1994-03-02 |
2011-07-21 |
Organon Nv |
Sublinguales oder bukkales arzneimittel.
|
JP3274579B2
(ja)
*
|
1995-01-12 |
2002-04-15 |
住友製薬株式会社 |
脳血管障害に伴う精神症候治療剤
|
US6057441A
(en)
*
|
1996-04-12 |
2000-05-02 |
Janssen Pharmaceutica, N.V. |
Substituted tetracyclic tetrahydrofuran derivatives
|
BR9809162A
(pt)
*
|
1997-05-26 |
2000-08-01 |
Akzo Nobel Nv |
Sal de trans-5-cloro-2, 3, 3a, 12b-tetrahidro-2-metil-1h-dibenz [2,3:6,7] oxepino[4,5-c] pirrol e agente formador de sal, composto, composição farmacêutica, e, preparação de injeção armazenável
|
HRP20020305A8
(en)
*
|
2002-04-10 |
2009-03-31 |
GlaxoSmithKline istra�iva�ki centar Zagreb d.o.o. |
2-thia-dibenzoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof
|
HRP20020441A2
(en)
*
|
2002-05-21 |
2003-12-31 |
Pliva D D |
1-oxa-dibenzoazulen as inhibitor of production of tumor necrosis factors and intermediate for preparation thereof
|
HRP20030160A2
(en)
*
|
2003-03-06 |
2005-04-30 |
Pliva-Istra�iva�ki institut d.o.o. |
1-thiadibenzoazulene derivatives and biological action thereof
|
MXPA05012317A
(es)
*
|
2003-05-16 |
2006-01-30 |
Pfizer Prod Inc |
Combinaciones terapeuticas de agentes antipsicoticos atipicos con agentes moduladores del gaba anticonvulsivos o benzodiazepinas.
|
HRP20030885A2
(en)
*
|
2003-11-03 |
2005-08-31 |
Pliva-Istra�iva�ki institut d.o.o. |
USE OF 2-THIA-DIBENZO[e,h]AZULENES FOR THE MANUFACTURE OF PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT AND PREVENTION OF CENTRAL NERVOUS SYYTEM DISEASES AND DISORDERS
|
HRP20030954A2
(en)
*
|
2003-11-21 |
2005-08-31 |
Pliva D.D. |
USE OF 1-AZA-DIBENZO[e,h]AZULENES FOR THE MANUFACTURENT AND PREVENTION OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS
|
HRP20030958A2
(en)
*
|
2003-11-21 |
2005-08-31 |
Pliva-Istra�iva�ki institut d.o.o. |
USE OF 1,3-DIAZA-DIBENZO[e,h]AZULENES FOR THE MANUFACTURE OF THE TREATMENT AND PREVENTION OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS
|
HRP20030956A2
(en)
*
|
2003-11-21 |
2005-08-31 |
Pliva-Istra�iva�ki institut d.o.o. |
USE OF 1,2-DIAZA-DIBENZO[e,h]AZULENES FOR THE MANU
|
HRP20030959A2
(es)
*
|
2003-11-21 |
2005-10-31 |
Pliva-Istra�iva�ki institut d.o.o. |
|
HRP20030957A2
(en)
*
|
2003-11-21 |
2005-08-31 |
Pliva-Istra�iva�ki institut d.o.o. |
USE OF 1-THIA-3-AZA-DIBENZO[e,h]AZULENES FOR THE MANUFACTURE OF PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT AND PREVENTION OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS
|
HRP20030953A2
(en)
*
|
2003-11-21 |
2005-10-31 |
Pliva-Istra�iva�ki institut d.o.o. |
PREPARATION OF 1-AZA-2-OXA-DIBENZO[e,h]AZULENES AND THEIR USE FOR THE MANUFACTURE OF PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT AND PREVENTION OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS
|
HRP20030955A2
(en)
*
|
2003-11-21 |
2005-08-31 |
Pliva-Istra�iva�ki institut d.o.o. |
USE OF 1-OXADIBENZO[e,h]AZULENES FOR THE MANUFACTURE OF PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT AND PREVENTION OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS
|
HRP20040104A2
(en)
*
|
2004-01-30 |
2005-10-31 |
Pliva-Istra�iva�ki institut d.o.o. |
Use of benzonaphthoazulenes for the manufacture of pharmaceutical formulations for the treatment and prevention of central nervous system diseases and disorders
|
BRPI0507609A
(pt)
*
|
2004-02-13 |
2007-07-03 |
Pfizer Prod Inc |
combinações terapêuticas de anti-psicóticos atìpicos com antagonistas de fator de liberação de corticotropina
|
MXPA06013163A
(es)
*
|
2004-05-11 |
2007-02-13 |
Pfizer Prod Inc |
Combinacion de antipsicoticos atipicos y antagonistas del receptor 5-ht1b.
|
KR20070084123A
(ko)
*
|
2004-10-15 |
2007-08-24 |
엔.브이.오가논 |
양극성 장애 및 관련 증상의 치료
|
SI1710245T1
(sl)
*
|
2005-04-07 |
2007-12-31 |
Organon Nv |
Kristalna oblika asenapin maleata
|
RS51341B
(en)
*
|
2005-04-07 |
2011-02-28 |
N.V. Organon |
INTERMEDIATE COMPOUNDS FOR THE TRANS-5-CHLOR-2-METHYL-2,3A, 12B-TETRAHYDRO-1H-DIBENZE [2,3; 6,7] OXEPINO [4,5-C] Pyrrole
|
US7872147B2
(en)
|
2005-04-07 |
2011-01-18 |
N. V. Organon |
Intermediate compounds for the preparation of trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1H-dibenz[2,3:6,7]oxepino[4,5-c]pyrrole
|
US7741358B2
(en)
*
|
2005-04-14 |
2010-06-22 |
N.V. Organon |
Crystal form of asenapine maleate
|
WO2007046554A1
(ja)
*
|
2005-10-21 |
2007-04-26 |
Sumitomo Chemical Company, Limited |
ジベンゾオキセピノピロール化合物の製造方法、その中間体及び該中間体の製造方法
|
TW200817414A
(en)
*
|
2006-07-05 |
2008-04-16 |
Organon Nv |
Process for the preparation of asenapine and intermediate products used in said process
|
US7750167B2
(en)
*
|
2006-07-05 |
2010-07-06 |
N.V. Organon |
Process for the preparation of asenapine and intermediate products used in said process
|
PE20081457A1
(es)
*
|
2006-10-06 |
2008-10-18 |
Organon Nv |
Asenapina amorfa, procesos para prepararlas y su uso para tratar trastornos del sistema nervioso central
|
US7875729B2
(en)
*
|
2007-01-05 |
2011-01-25 |
Synthon Bv |
Process for making asenapine
|
EP2170399A1
(en)
*
|
2007-06-05 |
2010-04-07 |
Synthon B.V. |
Intranasal administration of asenapine and pharmaceutical compositions therefor
|
JP5245428B2
(ja)
*
|
2007-07-06 |
2013-07-24 |
住友化学株式会社 |
トランス−ジベンゾオキセノピロール化合物の製造方法およびその中間体
|
JP2011508751A
(ja)
*
|
2008-01-04 |
2011-03-17 |
ナームローゼ・フエンノートチヤツプ・オルガノン |
アセナピンの調製方法および前記方法において使用される中間生成物
|
EP2254420A4
(en)
|
2008-02-20 |
2012-02-15 |
Targia Pharmaceuticals |
CNS PHARMACEUTICALS AND METHOD FOR THEIR USE
|
CA2727573A1
(en)
*
|
2008-06-25 |
2009-12-30 |
Pfizer Inc. |
Diaryl compounds and uses thereof
|
JP5801295B2
(ja)
*
|
2009-06-24 |
2015-10-28 |
メルク・シャープ・エンド・ドーム・ベー・フェー |
アセナピンを含有する注射可能な配合物およびそれを用いた処置方法
|
TW201118102A
(en)
|
2009-07-29 |
2011-06-01 |
Organon Nv |
Hydroxyasenapine compounds, derivatives thereof and pharmaceutical compositions comprising same
|
CA2802990A1
(en)
|
2010-06-18 |
2011-12-22 |
Dr. Reddy's Laboratories Ltd. |
Asenapine maleate
|
WO2012013766A1
(en)
|
2010-07-29 |
2012-02-02 |
Laboratorios Lesvi, S.L. |
Novel process for the preparation of asenapine
|
CA2818025A1
(en)
|
2010-11-15 |
2012-05-24 |
Agenebio, Inc. |
Pyridazine derivatives, compositions and methods for treating cognitive impairment
|
WO2012066565A2
(en)
|
2010-11-16 |
2012-05-24 |
Cadila Healthcare Limited |
Asenapine maleate amorphous and crystalline form and process for preparation thereof
|
EP2468750A1
(en)
|
2010-12-13 |
2012-06-27 |
Chemo Ibérica, S.A. |
Polymorphic forms of asenapine maleate and processes for their preparation
|
EP2468751B1
(en)
|
2010-12-24 |
2016-03-16 |
Medichem, S.A. |
Processes for the preparation of 5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1H-dibenzo[2,3:6,7]oxepino[4,5-c]pyrrole
|
WO2012123325A1
(en)
|
2011-03-11 |
2012-09-20 |
Medichem S.A. |
NEW CRYSTAL FORMS OF THE SALT OF TRANS-5-CHLORO-2-METHYL-2,3,3A,12b-TETRAHYDRO-1H-DIBENZO[2,3:6,7]OXEPINO[4,5-c]PYRROLE WITH MALEIC ACID
|
ITMI20110734A1
(it)
|
2011-05-02 |
2012-11-03 |
Olon Spa |
Sali cristallini di asenapina
|
EP2524919A1
(en)
*
|
2011-05-17 |
2012-11-21 |
Sandoz AG |
Novel crystalline salts of Asenapine with organic Di-acids and Tri-acids
|
EP2524921A1
(en)
*
|
2011-05-17 |
2012-11-21 |
Sandoz AG |
Novel Crystalline Salts of Asenapine
|
US9505771B2
(en)
|
2011-05-18 |
2016-11-29 |
Laboratories Lesvi S.L. |
Stable micronised monoclin form of asenapine maleate and its synthesis
|
US9533994B2
(en)
|
2011-05-18 |
2017-01-03 |
Laboratorios Lesvi S.L. |
Monoclinic crystalline form of asenapine maleate with a specific particle size distribution
|
WO2013024492A2
(en)
|
2011-07-01 |
2013-02-21 |
Megafine Pharma (P) Ltd. |
A process for the preparation of asenapine and novel salts thereof
|
US9145421B2
(en)
|
2011-07-20 |
2015-09-29 |
Ranbaxy Laboratories Limited |
Process for the preparation of asenapine maleate
|
WO2013035109A1
(en)
|
2011-09-08 |
2013-03-14 |
Mylan Laboratories Ltd |
Improved process for the preparation of asenapine maleate
|
WO2013041604A1
(en)
|
2011-09-21 |
2013-03-28 |
Sandoz Ag |
Crystal form of asenapine maleate
|
EP2572703A1
(en)
|
2011-09-21 |
2013-03-27 |
Hexal AG |
Compressed oral dosage form for asenapine maleate
|
AU2012346880A1
(en)
|
2011-11-28 |
2014-06-19 |
Sun Pharmaceutical Industries Limited |
Process for the preparation of asenapine intermediate
|
CN103254201B
(zh)
*
|
2012-02-21 |
2016-04-13 |
四川科伦药物研究有限公司 |
一种阿塞那平的制备方法
|
WO2013190481A1
(en)
*
|
2012-06-21 |
2013-12-27 |
Alembic Pharmaceuticals Limited |
Process for preparing asenapine and salts of intermediates thereof
|
ITMI20121810A1
(it)
|
2012-10-24 |
2014-04-25 |
Chemo Iberica Sa |
Poliformi di maleato di asenapina e processo per la loro preparazione
|
EP2919788A4
(en)
|
2012-11-14 |
2016-05-25 |
Univ Johns Hopkins |
METHODS AND COMPOSITIONS FOR THE TREATMENT OF SCHIZOPHRENIA
|
WO2014127786A1
(en)
|
2013-02-22 |
2014-08-28 |
Zentiva, K.S. |
Orally disintegrating pharmaceutical composition comprising asenapine
|
CN103113379A
(zh)
*
|
2013-03-12 |
2013-05-22 |
盛世泰科生物医药技术(苏州)有限公司 |
阿塞那平马来酸盐的合成工艺
|
CN103351393B
(zh)
*
|
2013-07-03 |
2016-04-06 |
华裕(无锡)制药有限公司 |
用于制备阿森那平之还原剂及阿森那平之制备方法
|
EP3083569B1
(en)
|
2013-12-20 |
2022-01-26 |
Agenebio, Inc. |
Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
|
CN103772400A
(zh)
*
|
2014-01-07 |
2014-05-07 |
万特制药(海南)有限公司 |
反式-5-氯-2,3,3a,12b-四氢-1H-二苯并[2,3:6,7]氧杂卓并[4,5-c]吡咯的制备方法
|
CN103772401A
(zh)
*
|
2014-01-07 |
2014-05-07 |
万特制药(海南)有限公司 |
11-氯-2,3,3a,12b-四氢-2-甲基-1H-二苯并[2,3:6,7]氧杂卓并[4,5-c]吡咯-1-酮的一种新精制方法
|
EP3307245A1
(en)
|
2015-06-11 |
2018-04-18 |
Alrise Biosystems GmbH |
Process for the preparation of drug loaded microparticles
|
WO2016205739A1
(en)
|
2015-06-19 |
2016-12-22 |
Belew Mekonnen |
Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
|
BR112019012821A2
(pt)
|
2016-12-19 |
2019-11-26 |
Agenebio Inc |
derivados de benzodiazepina, composições e métodos para o tratamento do comprometimento cognitivo
|
US20180170941A1
(en)
|
2016-12-19 |
2018-06-21 |
Agenebio, Inc. |
Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
|
KR102614709B1
(ko)
|
2016-12-20 |
2023-12-18 |
에르테에스 로만 테라피-시스테메 아게 |
아세나핀 및 폴리실록산 또는 폴리이소부틸렌을 함유하는 경피흡수 치료 시스템
|
CN110087640A
(zh)
|
2016-12-20 |
2019-08-02 |
罗曼治疗系统股份公司 |
包含阿塞那平的透皮治疗系统
|
US11033512B2
(en)
|
2017-06-26 |
2021-06-15 |
Lts Lohmann Therapie-Systeme Ag |
Transdermal therapeutic system containing asenapine and silicone acrylic hybrid polymer
|
CN112601749B
(zh)
|
2018-06-19 |
2024-03-26 |
艾吉因生物股份有限公司 |
用于治疗认知损害的苯并二氮杂环庚三烯衍生物,组合物和方法
|
KR20210022656A
(ko)
|
2018-06-20 |
2021-03-03 |
에르테에스 로만 테라피-시스테메 아게 |
아세나핀을 함유하는 경피 치료 시스템
|
CN110183457A
(zh)
*
|
2019-06-27 |
2019-08-30 |
浙江天顺药业有限公司 |
一种阿塞那平及其制备方法
|
CN110606852B
(zh)
|
2019-08-13 |
2021-02-05 |
浙江奥翔药业股份有限公司 |
制备阿塞那平的方法
|
US11679407B2
(en)
*
|
2020-06-26 |
2023-06-20 |
Intel Corporation |
Liquid metal thermal interface material application
|
WO2023006954A1
(en)
|
2021-07-30 |
2023-02-02 |
Fundació Institut D'investigació Biomèdica De Bellvitge (Idibell) |
Asenapine for use in cancer
|
WO2024039886A1
(en)
|
2022-08-19 |
2024-02-22 |
Agenebio, Inc. |
Benzazepine derivatives, compositions, and methods for treating cognitive impairment
|